Compare Eni SpA (E) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Eli Lilly And Co — how do they compare? Eni SpA trades at $55.64 (market cap $78.10B), while Eli Lilly And Co trades at $1,166.02 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 13.6× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.52%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Eli Lilly And Co for 93 Days on average.
| E | LLY | |
|---|---|---|
Market Cap | $78.10B | $1.06T |
Volume | 296,516 | 2,297,239 |
Sector | Energy | Health |
52-Week High | $57.61 | $1.28K |
52-Week Low | $34.03 | $799.57 |
Typical Hold Time | 53 Days | 93 Days |
Enterprise Value | $102.75B | $1.11T |
Dividend Yield | 4.52% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $55.62, up 1.96% today, amid a bearish technical signal. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. The company maintains solid cash flow and a low P/E of 12.53. Recent news highlights expansion in humanoid robotics, LNG projects in Argentina, and fuel discounts in Italy, indicating strategic diversification and customer support initiatives.
The outlook is mixed; valuation appears attractive with low multiples, and analyst consensus leans hold (61.53%). However, declining revenue, recent earnings misses, and bearish technicals pose near-term risks. Upside depends on execution of new projects and stabilization of energy markets, while volatility in oil prices remains a key sensitivity.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
